AC Immune (NASDAQ:ACIU) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday, October 19th.
Other research analysts have also recently issued reports about the company. HC Wainwright set a $18.00 price objective on AC Immune and gave the company a “buy” rating in a report on Thursday, August 9th. ValuEngine raised AC Immune from a “hold” rating to a “buy” rating in a research report on Friday, July 6th. Finally, Zacks Investment Research lowered AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. AC Immune has an average rating of “Hold” and a consensus target price of $14.00.
Shares of AC Immune stock traded down $0.16 on Friday, hitting $8.73. 34,063 shares of the company were exchanged, compared to its average volume of 111,650. AC Immune has a 1-year low of $7.16 and a 1-year high of $17.40. The stock has a market cap of $580.91 million, a P/E ratio of -29.10 and a beta of 1.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.65 and a quick ratio of 9.65.
Several institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in shares of AC Immune by 28.9% during the third quarter. FMR LLC now owns 5,209,673 shares of the company’s stock worth $41,678,000 after acquiring an additional 1,166,524 shares during the period. Janus Henderson Group PLC purchased a new position in AC Immune in the third quarter valued at $13,345,000. Artal Group S.A. increased its holdings in AC Immune by 25.0% in the third quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $6,000,000 after buying an additional 150,000 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new position in AC Immune in the third quarter valued at $626,000. Finally, JPMorgan Chase & Co. purchased a new position in AC Immune in the third quarter valued at $142,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also: Fiduciary
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.